Literature DB >> 30805400

Subcutaneous Immunization with Recombinant Lactococcus lactis Expressing F1S1 Fusion Protein Induces Systemic and Mucosal Immune Responses in BALB/C Mice.

Ali Torkashvand1, Fariborz Bahrami2, Minoo Adib1, Soheila Ajdary2.   

Abstract

BACKGROUND: Lactic acid bacteria such as Lactococcus (L.) lactis are powerful tools that can function as live delivery vectors and heterologous protein expression hosts in development of novel vaccines. Pertussis toxin (PT) and filamentous hemagglutinin (FHA) are important virulence factors of Bordetella (B.) pertussis and constitute the major components of commercially available acellular pertussis (aP) vaccines. The purpose of the present study was to express F1S1 fusion protein, consisted of the N-terminal region of S1 subunit from PT and FHA type 1 immunodominant domain by L. lactis and to evaluate its immunogenicity.
METHODS: The fusion gene composed of sequences encoding the F1S1 and the signal peptide of usp45 fragments (SECF1S1) was codon optimized for protein production in L. lactis and was synthesized and inserted in-frame inside pNZ8149 plasmid. The resulting pNZ8149-SECF1S1 construct was introduced by electroporation into L. lactis cells (LL-F1S1). BALB/c mice were subcutaneously immunized with LL-F1S1 or commercial DTaP vaccine. The immune responses were investigated.
RESULTS: The LL-F1S1-immunized mice produced significant levels of specific IFN-g compared to their respective controls and DTaP-immunized mice. The F1S1- specific IgG antibody response was lower in LL-F1S1-immunized mice while the IgG2a/IgG1 ratio was higher in this group compared to the DTaP-immunized mice. Moreover, anti-F1S1 IgA antibodies were only detected in the lung homogenates of the LL-F1S1-immunized mice, suggesting the induction of a mucosal immune response.
CONCLUSION: These results indicate the feasibility of expression of F1S1 fusion protein in L. lactis. This recombinant bacterium could induce mucosal and Th1-type systemic immune responses following subcutaneous administration.

Entities:  

Keywords:  Bordetella pertussis; FHA; Lactococcus lactis; Pertussis toxin

Year:  2019        PMID: 30805400      PMCID: PMC6374061     

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  32 in total

Review 1.  Regional specialization in the mucosal immune system: what happens in the microcompartments?

Authors:  P Brandtzaeg; E S Baekkevold; I N Farstad; F L Jahnsen; F E Johansen; E M Nilsen; T Yamanaka
Journal:  Immunol Today       Date:  1999-03

Review 2.  Immunity to Bordetella pertussis.

Authors:  K H Mills
Journal:  Microbes Infect       Date:  2001-07       Impact factor: 2.700

3.  DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.

Authors:  Kazunari Kamachi; Toshifumi Konda; Yoshichika Arakawa
Journal:  Vaccine       Date:  2003-11-07       Impact factor: 3.641

4.  Expression of a C terminally truncated form of pertussis toxin S1 subunit effectively induces protection against pertussis toxin following DNA-based immunization.

Authors:  Kazunari Kamachi; Yoshichika Arakawa
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

5.  Immunoglobulin A-mediated protection against Bordetella pertussis infection.

Authors:  S M Hellwig; A B van Spriel; J F Schellekens; F R Mooi; J G van de Winkel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1.

Authors:  C Daniel; A Repa; C Wild; A Pollak; B Pot; H Breiteneder; U Wiedermann; A Mercenier
Journal:  Allergy       Date:  2006-07       Impact factor: 13.146

7.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

8.  Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.

Authors:  Andreas Repa; Corinne Grangette; Catherine Daniel; Romana Hochreiter; Karin Hoffmann-Sommergruber; Josef Thalhamer; Dietrich Kraft; Heimo Breiteneder; Annick Mercenier; Ursula Wiedermann
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

9.  Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice.

Authors:  Jean-Marc Chatel; Sebastien Nouaille; Karine Adel-Patient; Yves Le Loir; Herman Boe; Alexandra Gruss; Jean-Michel Wal; Philippe Langella
Journal:  Appl Environ Microbiol       Date:  2003-11       Impact factor: 4.792

10.  Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.

Authors:  Praveen Mannam; Kevin F Jones; Bruce L Geller
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more
  3 in total

Review 1.  Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories.

Authors:  Sofia O D Duarte; Gabriel A Monteiro
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

Review 2.  Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.

Authors:  Romina Levit; Naima G Cortes-Perez; Alejandra de Moreno de Leblanc; Jade Loiseau; Anne Aucouturier; Philippe Langella; Jean Guy LeBlanc; Luis G Bermúdez-Humarán
Journal:  Gut Microbes       Date:  2022 Jan-Dec

3.  Vaccination in Leishmaniasis: A Review Article.

Authors:  Latifeh Abdellahi; Fariba Iraji; Anahita Mahmoudabadi; Seyed Hossein Hejazi
Journal:  Iran Biomed J       Date:  2022-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.